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Incidence of Cardiovascular and Cerebrovascular Events Associated
With Sirolimus Use After Liver Transplantation
A. Weicka, W. Chacrab, A. Kuchipudia, M. Elbattaa, G. Divinec, C. Burmeisterc, and D. Moonkab,*
a
Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan; bDivision of Gastroenterology and Hepatology, Henry Ford
Hospital, Detroit, Michigan; and cPublic Health Sciences, Henry Ford Hospital, Detroit, Michigan

ABSTRACT
Background. Sirolimus (SRL) is an immunosuppressant often used in liver transplantation (LT) to mitigate renal insufﬁciency associated with calcineurin inhibitors.
Sirolimus can cause hyperlipidemia, but its association with coronary artery disease (CAD)
and cerebrovascular accidents (CVAs) is unclear. The purpose of this study was to assess
the risk of CAD and CVAs with the use of SRL in LT recipients.
Methods. We retrospectively reviewed all of our LT recipients from 2000 to 2011. Patients
with multiorgan transplant, multiple liver transplants, everolimus therapy, or survival <3 months
were excluded. The 803 remaining patients were divided into 3 groups: 1) 134 patients who
received and tolerated SRL; 2) 604 patients who never received SRL; and 3) 65 patients who
started but discontinued SRL. The primary outcome was the development of CAD or CVA
beyond 4 months after transplantation with the use of time-dependent Kaplan-Meier analysis.
Results. In group 1, there were 6 CAD and 2 CVA events; in group 2, 27 CAD and 16 CVA
events; and in group 3, 10 CAD and 2 CVA events. The event-free survival for CAD/CVA at 1,
3, and 5 years was 100%, 98.1%, and 97.2% respectively for group 1; 99.7%, 98.4%, and 96.1%
for group 2; and 92.3%, 92.3%, and 85.6% for group 3. On an unadjusted basis, compared with
group 2, there was no difference in CAD/CVA rates in group 1 (hazard ratio [HR] 0.92; not
signiﬁcant), but there was an increase in group 3 (HR 2.94; P ¼ .0019). However, on
multivariate analysis, only age at transplantation (HR 1.06; P ¼ .001) and diabetes before
transplantation (P ¼ .011) were associated with increased CAD/CVA risk.
Conclusions. Our analysis showed that patients receiving SRL after LT had no increased risk
of CAD/CVA events compared with patients maintained on a calcineurin inhibitor. The risk of
CAD/CVA should not be a factor in avoiding SRL.

S

IROLIMUS (SRL) is a potent immunosuppressive agent
that inhibits the mammalian target of rapamycin
(mTOR), a mechanism different than that of calcineurin inhibitors (CNIs). CNIs are associated with renal insufﬁciency
after solid organ transplantation [1]. Sirolimus may be used as
an alternative for CNIs when renal insufﬁciency develops or is
of concern. It has been associated with improved renal function
after transplantation [2e4].
The potential beneﬁts of SRL do not come without risks.
Numerous side effects have been linked to SRL, including
delayed wound healing and hepatic artery thrombosis.
Hyperlipidemia is another side effect that can be observed
in up to 49% of patients on SRL long term [5,6]. The consequences of this increased incidence of hyperlipidemia
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have not been well established, especially in the posteliver
transplantation community. One study has demonstrated
that even with increased Framingham Risk Model scores for
myocardial infarction risk, patients receiving SRL for liver
transplant do not have increased incidence of myocardial
infarction; however, that was not a time-dependent analysis
[7]. The relationship between SRL and cerebrovascular
accident (CVA) incidence was also evaluated in the heart
transplant community, with no increased risk of CVA
observed, but that evaluation was based more on a
*Address correspondence to Dilip Moonka, MD, Henry Ford
Hospital, 2799 W Grand Blvd, Detroit, MI 48202. E-mail:
dmoonka1@hfhs.org
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Table 1. Patient Demographics and Baseline Characteristics
Characteristics

Group 1

Group 2

Group 3

P Value, Group 1 vs Group 2

Age at transplantation, y
Male
Race
White
Black
Other
Hepatitis C virus
Hepatocellular carcinoma
Alcohol use
NASH
BMI, kg/m2
Diabetes before transplantation
Hypertension before transplantation
Hyperlipidemia before transplantation
CVA before transplantation
CAD before transplantation
MELD at transplantation
Dialysis at transplantation
Creatinine at transplantation (mg/dL)
GFR at transplantation (mL/min/1.73m2)
Proteinuria at transplantation
Donor age, y
In hospital at transplantation
Days from treatment to attempted sirolimus

54.1  10.5
96 (71.6%)

53.5  10.0
391 (64.7%)

55.5  8.4
43 (66.2%)

.5097
.1268

90 (67.2%)
37 (27.6%)
7 (5.2%)
51 (38.4%)
38 (28.6%)
48 (35.8%)
5 (3.8%)
28.0  6.4
35 (26.5%)
48 (36.4%)
16 (12.2%)
1 (0.9%)
2 (1.9%)
20.1  8.5
3 (2.2%)
1.4  0.9
72.1  43.6
7 (10.8%)
42.0  17.8
28 (20.9%)
472.8  611.4

398 (65.9%)
151 (25.0%)
55 (9.1%)
276 (46.8%)
155 (26.2%)
205 (33.9%)
29 (4.9%)
29.0  6.1
121 (20.5%)
167 (28.3%)
30 (5.1%)
9 (1.8%)
26 (5.1%)
19.6  7.8
19 (3.2%)
1.2  0.7
80.2  39.7
52 (14.7%)
42.8  17.0
117 (19.6%)

46 (70.8%)
15 (23.1%)
4 (6.2%)
16 (24.6%)
9 (13.9%)
30 (46.2%)
3 (4.6%)
28.2  5.9
26 (40.6%)
25 (39.1%)
5 (7.8%)
1 (1.6%)
6 (9.2%)
21.4  8.3
6 (9.2%)
1.7  1.1
54.7  31.4
7 (15.2%)
45.1  15.9
15 (23.1%)
310.5  417.2

.3186

.0775
.5806
.6782
.5645
.1222
.1271
.0655
.0025
1.0000
.2015
.4966
.7809
.0018
.0136
.4036
.6363
.7336

Note. Values are presented as mean  SD or n (%).
Abbreviations: NASH, non-alcoholic steatohepatitis; BMI, body mass index; CVA, cardiovascular accident; CAD, coronary artery disease; MELD, Model for EndStage Liver Disease score; GFR, glomerular ﬁltration rate.

purported link between SRL and thrombotic microangiopathy rather than hyperlipidemia [8,9].
Given that hyperlipidemia is associated with increased
risk of coronary artery disease (CAD) and CVA in the
general population, we sought to assess the time-dependent
risk of CAD and CVA with the use of SRL in our liver
transplant population.

PATIENTS AND METHODS
We conducted a retrospective chart review of 1,053 patients who
received a liver transplant at our center from the years 2000 to 2011
to allow for adequate follow-up. Patients were excluded as follows:
59 patients with combined liver-kidney transplant, 94 with multiple
liver transplants, 19 who received everolimus therapy, 45 with posttransplantation survival <3 months, and 2 with follow-up <3
months. Thus, 803 patients were included in the ﬁnal analysis and
were divided into 3 groups. Group 1 included 134 patients (16.7%)
who were converted to SRL, tolerated it, and were maintained on
the drug. Group 2 included 604 patients (75.2%) who did not
receive SRL at any point. Group 3 included 65 patients (8.1%) who
were converted to SRL but did not tolerate it or discontinued it for
any reason. The primary composite outcome was the development
of CAD or CVA occurring beyond 4 months after transplantation
with the use of time-dependent Kaplan-Meier analysis, meaning
that patients were evaluated based on the group they belonged to at
the time of CAD or CVA event. Demographic and transplant data
were used to perform multivariate Cox regression modeling of
signiﬁcant factors. This study was reviewed and approved by the
Institutional Review Board at the study facility.

RESULTS

Table 1 highlights demographic data for all 3 groups. P values
are indicated within the table and reﬂect comparison between
group 1 and group 2 only. For numeric values, means are
reported with standard deviation in parentheses, and for
categoric variables frequency is reported with percentage in
parentheses. Patients in group 1 were more likely to have
hyperlipidemia before transplantation than patients in group 2
and had higher creatinine and lower glomerular ﬁltration rate
Table 2. Reasons for Discontinuing Sirolimus
Reason

Surgery
Recurrent hernia
Hyperlipidemia
Rash
Rejection
Poor wound healing
Infection
Malignancy
Pneumonitis
Diarrhea
Recurrent Edema/ascites
Neutropenia
Recurrent DVTs
Acute kidney injury
Initiation of antiviral therapy
Abbreviation: DVT, deep vein thrombosis.
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n (%)

11
9
8
7
6
4
3
3
3
3
3
2
1
1
1

(16.9%)
(13.8%)
(12.3%)
(10.8%)
(9.2%)
(6.2%)
(4.6%)
(4.6%)
(4.6%)
(4.6%)
(4.6%)
(3.1%)
(1.5%)
(1.5%)
(1.5%)
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Fig 1. Group assignment and total
events. Abbreviations: CAD, coronary
artery disease; CVA, cerebrovascular
accident.

(GFR). Interestingly, patients in group 3, in whom SRL was
stopped, had the worst renal function before transplantation.
Patients in group 3 were also more likely to have diabetes and
hypertension before transplantation, although only the former
was signiﬁcant. A separate analysis was performed comparing
groups 1 and 3 to identify factors that might identify patients
who did not tolerate or discontinued SRL. On multivariate
analysis, the only factor that was associated with SRL discontinuation was a higher GFR at transplantation, with an odds
ratio of 1.015 per mL/min GFR (conﬁdence interval
1.005e1.025; P ¼ .004).
Table 2 presents the reasons for discontinuation of sirolimus in group 3. In the cases of SRL being stopped for
surgery, the initial goal was to resume SRL after the surgery.
However, in all cases, the patient either elected not to
resume the drug or a surgical or medical complication
ensued that precluded SRL resumption. This is in contrast
to the patients with recurrent hernias, where the decision
was made up front to discontinue SRL indeﬁnitely. In patients who discontinued SRL for hyperlipidemia, mean
cholesterol levels before SRL conversion were 181 
64.1 mg/dL and were 289.5  68.7 mg/dL after SRL conversion despite medical therapy. This difference was significant (P ¼ .005). For the 3 patients who were discontinued
for malignancy, SRL was stopped to markedly limit immunosuppression. This was before the potential antineoplastic
effect of SRL was appreciated.

In group 1, there were a total of 6 CAD and 2 CVA
events, in group 2 27 CAD and 16 CVA events, and in group
3 10 CAD and 2 CVA events, as shown in Fig 1. The timedependent event-free survival for CAD/CVA at 1, 3, and 5
years was, respectively, 100%, 98.1%, and 97.2% for group
1; 99.7%, 98.4%, and 96.1% for group 2; and 92.3%, 92.3%,
and 85.6% for group 3. Figure 2 shows Kaplan-Meier eventfree survival curves for all groups for the combined events.
The event-free survival for CAD alone at 1, 3, and 5 years
was, respectively, 97.5%, 97.5%, and 96.4% for group 1;
99.6%, 98.7%, and 97.6% for group 2; and 88.9%, 79.0%,
and 72.8% for group 3. For CVA alone, the event-free
survival rate was 100% for all of 1, 3, and 5 years for
group 1; 99.7%, 99.3%, and 99.0% for group 2; and 100%,
100%, and 96.7% for group 3. On an unadjusted basis,
compared with group 2, there was no difference in CAD/
CVA rates in group 1 (hazard ratio [HR] 0.92; nonsigniﬁcant) but there was an increase in CAD/CVA in group 3
(HR 2.94; P ¼ .0019). On multivariate analysis, the only
variables associated with an increased risk of CAD/CVA
after liver transplantation was age at transplantation (HR
1.06; P ¼ .001) and diabetes before transplantation (P ¼
.011). Only 1 death was directly attributable to a cardiovascular event, and it was in group 2.
Hyperlipidemia was more common in the patients who
received SRL. Rates of hyperlipidemia and statin use after
transplantation were, respectively, 40.3% and 35.1% in
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Fig 2. Event-free survival for combined coronary artery disease
(CAD) and cerebrovascular accident (CVA) events after transplantation. The y axis represents event-free survival as a percentage of total patients who did not experience either a CVA or CAD
event. The x axis represents number of years after transplantation. The ﬁgure graphically represents group 1 “On SRL,” with
a dotted line; group 2, “No SRL,” with a solid line; and group 3,
“SRL Stopped,” with a dashed line. Abbreviation: SRL, sirolimus.

group 1, 19.5% and 10.4% in group 2, and 40.0% and 30.8%
in group 3. We deﬁned hyperlipidemia as the use of a statin
drug or cholesterol >225 mg/dL or triglycerides >200 mg/
dL on multiple occasions.
The mean time from transplantation to initiation of SRL
was 473 days for group 1, compared with 310 days for group
3, with a P value of .0143. No patients were started on SRL
de novo after transplantation. Group 1 patients were followed for a mean of 5.85 total years after transplantation,
with a mean of 4.63 years on SRL, for a total of 784 patientyears and 611 patient-years on SRL. Group 2 patients were
followed for a mean of 4.79 years after transplantation for
2,895 total patient-years. Group 3 patients were followed for
a mean of 5.62 years after transplantation for a total of 365
patient-years. Overall survival in our study population was
93.4% at 1 year, 85.0% at 3 years, and 77.1% at 5 years. A
separate survival analysis was run with the use of groups 1
and 3 to determine if there was an impact on the time from
transplantation to SRL conversion on death, CVA, and
CAD outcomes. There was no evidence of an association
between time to SRL conversion and death (P ¼ .472),
CVA (P ¼ .564), or CAD (P ¼ .434).
DISCUSSION

Our analysis shows that patients receiving SRL after liver
transplantation had no increased risk of clinically apparent
CAD or CVAs compared with patients maintained on a
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CNI. Our ﬁndings are consistent with an earlier study that
did not show an association between cardiovascular events
and SRL use after liver transplantation [7]. However, it
should be noted that our ﬁndings are based on a timedependent analysis that reﬂects the time patients received
SRL. This mode of analysis was not used in the earlier study
[7]. We conclude that the risk of CAD/CVA should not be a
factor in avoiding SRL. Age at transplantation and diabetes
before transplantation are readily identiﬁable and we have
demonstrated these to be independent risk factors for CAD/
CVA. These patients may warrant closer scrutiny and
intervention in the post-transplantation setting.
Looking more closely at our results, we have shown that
the risk of CVA, at least in the 5-year post-transplantation
range, is low in all groups. The risk is not affected by
whether patients are or are not on SRL, clearly demonstrated by 100% of the patients who were able to tolerate
sirolimus being CVA-free at 5-year follow-up. It is worth
noting that rates of hyperlipidemia were higher in patients
on SRL but that even patients who never saw SRL (group 2)
had an incidence of hyperlipidemia of 20%.
There are signiﬁcant limitations to our study. Our analysis
is limited by study time frame. Although we had a large
subset of patients available for review, it is possible that a
follow-up time of 5 years is not sufﬁcient to demonstrate an
increased risk of CAD/CVA associated with SRL, which is
supported by the relatively low rate of CAD/CVA events
seen in our population. Studies focused on CAD/CVA risk
in patients on SRL for longer than 5 years are warranted.
Furthermore, this study was not prospective or randomized.
Patients were typically converted to SRL because of concerns about renal function or a history of hepatocellular
carcinoma. The patients in group 3 who stopped SRL were
initially meant to be a de facto control for patients on SRL.
However, they clearly were more ill at the time of liver
transplantation and therefore do not represent an appropriate comparison.
It is possible that no randomized studies will be performed
with adequate power or duration to determine whether there
is an increased risk of CVA/CAD in SRL patients. In the
meantime, our data does not show such an association.
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